

Perspective

From structure to aetiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease

Susanne Herbst^{1,2,3} and  Patrick A. Lewis^{1,2,3}

¹Department of Comparative Biomedical Science, Royal Veterinary College, Royal College Street, London, U.K.; ²Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, U.K.; ³Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, U.S.A.

Correspondence: Patrick A. Lewis (plewis@rvc.ac.uk)



Since the discovery of mutations in leucine-rich repeat kinase 2 (LRRK2) as an underlying genetic cause for the development of Parkinson's disease (PD) in 2004 (Neuron **44**, 601–607; Neuron **44**, 595–600), and subsequent efforts to develop LRRK2 kinase inhibitors as a therapy for Parkinson's (Expert Opin. Ther. Targets **21**, 751–753), elucidating the atomic resolution structure of LRRK2 has been a major goal of research into this protein. At over 250 kDa, the large size and complicated domain organisation of LRRK2 has made this a highly challenging target for structural biologists, however, a number of recent studies using both *in vitro* and *in situ* approaches (Nature **588**, 344–349; Cell **182**, 1508–1518. e1516; Cell **184**, 3519–3527.e3510) have provided important new insights into LRRK2 structure and the complexes formed by this protein.

Leucine-rich repeat kinase 2 (LRRK2) has proven to be a protein of interest for a number of reasons. First and foremost, the *LRRK2* locus on chromosome 12 has been either directly linked or strongly implicated in heightened risk for a range of human diseases, most notably Parkinson's disease [1–3], and most recently progressive supranuclear palsy [4]. Intriguingly, the *LRRK2* locus makes a pleiotropic contribution to the risk of Parkinson's disease with autosomal coding mutations causing Parkinson's, coding polymorphisms strongly increasing lifetime risk, and non-coding variation more subtly increasing risk as identified by genome-wide population studies [5]. This latter observation is of particular significance, as it implies that the physiological function of LRRK2 may contribute to the disease process in Parkinson's, although the functional consequences of the non-coding variants at the *LRRK2* locus are as yet poorly understood [6]. Overall, the extant genetic data highlight LRRK2 as a potential therapeutic target not just for those with causative mutations, but also with the idiopathic form of the disorder. For fundamental biologists, the complex domain architecture and dual enzymatic activities of LRRK2 [7] (Figure 1) make it both an enthralling and an intimidating protein to study. In common with the other members of the ROCO protein family, and with the receptor-interacting protein kinases (RIPKs — with which LRRK2 is also affiliated), LRRK2 is likely to act as a signalling hub, co-ordinating and controlling myriad transduction pathways within the cell [8–10].

Ever since the identification of mutations in LRRK2 it has been clear that structural insights into the functions of the different domains of this protein, the interplay between them, and the impact of mutations upon these functions, would be critical for fully understanding the cellular role and pathophysiology of LRRK2. While the requirement for atomic resolution structural data relating LRRK2 was obvious, achieving this has been a herculean undertaking. This was due principally to the challenge presented by expressing and purifying such large protein (in excess of 250 kDa, and likely to be at least partially active as a dimer with the complex weighing in at over half a megadalton), a challenge perhaps exacerbated by the cytotoxic impact of expressing LRRK2 [11,12].

Received: 26 May 2021
 Revised: 12 July 2021
 Accepted: 15 July 2021

Version of Record published:
 30 July 2021




Figure 1. The domain organisation of LRRK2.

An ideogram of LRRK2 with coding variants associated with Mendelian disease (red), increased risk of Parkinson's (purple), and decreased risk of Parkinson's (green). LRR, leucine-rich repeats; ROC, Ras of complex proteins; COR, C-terminal of ROC.

Initial progress on the elucidating the three-dimensional atomic resolution organisation of LRRK2 relied on either purifying isolated domains or examining orthologous proteins (or both), with crystal structures for the ROC domain of LRRK2 [13] and of the ROC–COR fragment from a prokaryotic ROCO protein from *Chlorobium tepidum* published in 2008 [14], and the kinase domain of a LRRK from the amoeba *Dictyostelium discoideum* published in 2012 [15]. A further structure for the ROC domain of LRRK2 came in 2014 [16]; however, it was not until 2016 that the first model for full-length LRRK2 was proposed, based upon a 33 Å negative stain electron microscopy reconstruction, a crystal structure for the eponymous leucine-rich repeats isolated from *C. tepidum*, and mass spectrometry mapping of interactions across the LRRK2 complex [17]. Further cryoEM analyses allowed the reconstruction of LRRK2 at 24.2 Å [18]. A structure for the WD40 protein interaction domain followed in 2019 [19], alongside a structure for the LRR–ROC–COR domains of the *C. tepidum* ROCO protein (which naturally lacks a kinase domain) [20]. These structures (summarised in Table 1 and Figure 2) provided important insights into LRRK2 function at the molecular level, but did not

Table 1. Extant structures for LRRK2, including individual domains and orthologous proteins

Year	Domains	Species	Resolution	Technique	PDB	Reference
2008	ROC	<i>H. sapiens</i>	2.0 Å	X ray crystallography	2ZEJ	[13]
2008	ROC–COR	<i>C. tepidum</i>	2.90 Å	X ray crystallography	3DPU	[14]
2012	Kinase	<i>D. discoideum</i>	1.8 Å	X ray crystallography	4FOG	[15]
2016	Full length	<i>H. sapiens</i>	33 Å	CryoEM	NA	[17]
2016	LRR	<i>C. tepidum</i>	2.3 Å	X ray crystallography	5IL7	[17]
2017	Full length	<i>H. sapiens</i>	24.2 Å	CryoEM	NA	[18]
2019	ROC	<i>H. sapiens</i>	1.6 Å	X ray crystallography	6OJE	[16]
2019	WD40	<i>H. sapiens</i>	2.6 Å	X ray crystallography	6DLO	[19]
2019	LRR–ROC–COR	<i>C. tepidum</i>	3.29 Å	X ray crystallography	6HLU	[20]
2020	ROC–COR–Kinase–WD40	<i>H. sapiens</i>	3.50 Å	CryoEM	6VNO	[39]
2020	Full length	<i>H. sapiens</i>	14 Å	CryoEM	6XR4	[40]
2021	Full length	<i>H. sapiens</i>	3.7 Å	CryoEM	7LHW	[41]
2021	Full length	<i>H. sapiens</i>	3.5 Å	CryoEM	7LHT	[41]




Figure 2. A timeline for LRRK2 structural biology.

Timeline for structural advances in the LRRK2 field from the discovery of mutations in 2004 through to the present day. Details for each structure are noted in Table 1. Images generated from PDB files using Chimera [38], model for full-length LRRK2 from reference [17] courtesy of Johannes Gloeckner.

yield a clear picture of the mechanisms coordinating LRRK2 activities or define a consistent impact of mutations.

Pathogenic LRRK2 mutations in the kinase domain (G2019S and I2020T) sit within the kinase activation loop, thereby providing a putative structural explanation for altered kinase activity. In contrast, the LRRK2 GTPase function of LRRK2 remains enigmatic, and therefore the underlying mechanisms whereby mutations in the GTPase domain influence LRRK2 activity has been harder to define.

GTPases act as molecular switches that cycle between a GDP-bound inactive state and a GTP-bound active state. In the case of small GTPases, the nucleotide cycle is controlled by guanine-nucleotide exchange factors (GEFs) which aid the exchange of GDP to GTP and GTPase-activating proteins (GAPs) which promote GTP hydrolysis [21]. However, there has been no consistent identification of GEFs or GAPs for LRRK2 and a commonly occurring Glutamine in the G3-motif of the GTPase which is required for the GTPase-GAP interaction is not conserved and instead replaced by an Arginine residue, R1398, in LRRK2. Additionally, the amino acid substitution of R1398 to Leucine, an experimental approach commonly used in small GTPase research to achieve a constitutively active GTP-bound state, results in increased GTP hydrolysis and GTPase inactivation in LRRK2 [22,23], further indicating that the mechanism of GTP hydrolysis by LRRK2 is distinct from small GTPases. Based on the homology of LRRK2 to the *C. tepidum* ROCO protein, it has been suggested that LRRK2 instead acts as a G-protein activated by nucleotide-dependent dimerisation (GAD) [24]. The GAD GTPase mechanism requires dimerisation for GTP hydrolysis whereas GEFs and GAPs are not required. Instead, residues of the protomers of a dimer pair are thought to complement each other's active site, aiding GTP hydrolysis either by stabilising the protein structure or directly providing catalytic residues [24]. Dimerisation is thought to be a requirement for LRRK2 function [25], strengthening this hypothesis. However,

the composition of the dimer interface or how individual residues contribute to the catalytic mechanism remains unknown, highlighting the crucial importance of gaining structural insights into LRRK2 dimer contact sites for elucidating the LRRK2 enzymatic function.

Recently, major advances in elucidating the LRRK2 structure have been achieved. Deniston et al. [39] published a cryo-electron microscopy (EM) structure of a LRRK2 ROC–COR–Kinase–WD40 construct at a resolution of 3.5 Å, which was accompanied by an *in situ* structure of the full-length human LRRK2 I2020T mutant bound to microtubules at a resolution of 14 Å published by Watanabe et al. [40]. And more recently, Myasnikov et al. [41] resolved a full-length LRRK2 cryo-EM structure at a resolution of 3.7 Å and 3.5 Å for monomer and dimer, respectively. These structures break through the resolution limits that have hindered LRRK2 research, and expand our knowledge of the spatial relationship between the domains of LRRK2. Importantly, all three structures highlight a close proximity between the ROC–COR and the kinase domain pointing to a structural basis for the previously reported functional cross-talk between the LRRK2 ROC and kinase domains. The structures explore LRRK2 protomer interfaces in different complexes, a trimeric complex in case of the structure by Deniston et al., a multimeric helical complex in case of the *in situ* structure, and a dimeric complex for the full-length protein. All three structures identify a COR:COR domain interface mediating complex formation, with the full-length structure allowing to map individual residues of the dimer interface. The nature of the COR:COR interface is consistent with the proposed GAD mechanism for GTP hydrolysis, and was also predicted by the *C. tepidum* ROCO protein ROC–COR tandem structure. The ROCO protein structure further predicted that the GTP cycle results in conformational changes that bring the ROC domains of each dimer pair into close contact creating a ROC:ROC domain interface mediating GTP hydrolysis [14,20] (Figure 2, 3DPU). The position of the ROC domains in the dimer of the LRRK2 *in situ* and cryo-EM structures do not, however, map onto the ROCO protein models (Figure 2, 7LHTY). The ROC domains in the LRRK2 dimer structures do not come into close proximity which would be required for GTP hydrolysis aided by *trans* activation, suggesting that in the context of these structures at least, each ROC domain of LRRK2 as an independent catalytic unit. It is of note that the orientation of the ROC/COR domains is remarkably similar to a structural model of whole human LRRK2 that integrated experimental constraints provided by chemical crosslinking [17] (Figure 2). In addition, the LRRK2 full-length structure also allows to map pathogenic mutations in the ROC–COR domain. Interestingly, the residues mutated in the ROC domain, R1441 and N1437, cluster in a helix which faces the COR domain and in particular the COR domain residue Y1699 indicating that the positioning of this helix might have an impact on the ability of LRRK2 to hydrolyse GTP.

However, comparing the structure of the LRRK2 ROC–COR–Kinase–WD40 construct to the full-length structure, the position of the ROC–COR domain in relationship to the kinase domain and WD40 differs in the full-length structure, highlighting the functional importance of the LRRK2 accessory domains. This is of particular interest in the context of the G2385R risk variant, located in the WD40 domain [26]. The arginine substitution at this residue is very clearly associated with heightened risk of developing PD in East Asian populations, but what is driving this risk at a molecular level remains unclear [27].

The recent full-length LRRK2 structure from Myasnikov and co-workers allows to map domain interfaces. Of the previously unresolved regions in LRRK2, the Leucine-rich repeat domain is particularly prominent, as it appears to shield the kinase domain from substrate entry and to stabilise a kinase-inactive conformation. Further, it acts as major hub for domain–domain interactions, by containing a helix, termed ‘hinge helix’ by Myasnikov et al., that bridges the Ankyrin-repeat, Armadillo-repeat, and the WD40 domain. Additionally, the presence of the hinge helix generates steric clashes when modelled onto a previously reported WD40:WD40 dimer structure [19]. The WD40:WD40 interface, which was also described in the *in situ* structure, mediates the formation of large multimeric filamentous LRRK2 complexes which form around microtubules under specific experimental conditions or in specific LRRK2 mutation backgrounds. The full-length structure indicates that the position of the LRR domain is not compatible with a WD40:WD40 homodimerization interface, at least in the reported kinase-inactive state. This raises the question as to whether the LRR domain will undergo major conformational changes upon LRRK2 activation, and under what cellular circumstances the filamentous form of LRRK2 becomes the physiologically predominant species.

Watanabe et al. focused on the LRRK2 microtubule interaction as this allowed for correlative light and electron microscopy imaging. For this form, little is known about LRRK2 kinase activity, and it is currently not clear if known LRRK2 substrates, in particular Rab GTPases, could access LRRK2 in a microtubule-bound multimeric complex. A recent study examining the role of LRRK2 in microtubule-mediated vesicle transport questions the conclusion drawn by Deniston et al., that LRRK2 might serve as a roadblock of microtubule-mediated

transport. It suggests that LRRK2 facilitates anterograde transport of autophagosomes along microtubules [28]. However, Boecker et al. study LRRK2 recruited to autophagosomal membranes and its requirement for recruiting adaptor proteins of microtubule transport rather than a direct interaction of LRRK2 with microtubules. Given that recruitment of LRRK2 to endolysosomes now can be robustly achieved using chemical agents that stress lysosomal homeostasis [29,30], it is likely future LRRK2 *in situ* structures that explore this aspect of LRRK2 biology will provide significant insights. In contrast to the microtubule-bound form of LRRK2, the activation status of LRRK2 recruited to endolysosomal vesicles is better characterised, as LRRK2 membrane association is associated with kinase activity [25,31–33]. Additionally, a membrane-bound structure would be predicted to shed further light into the function and position of some of the LRRK2 accessory domains, as they are predicted to be involved in membrane association.

An endomembrane-bound structure might also help to overcome the next hurdle for LRRK2 biology: capturing the protein in a kinase active conformation at a higher resolution than the previous *in situ* structure allowed for. LRRK2 being captured in an inactive conformation in the full-length cryo-EM structure could be a consequence of the structure being solved in a GDP-bound inactive state. GTP-binding is thought to mediate intra- and inter-domain movements as seen for other ROCO proteins and directly affects LRRK2 kinase activity [20]. Additionally, recent work indicated that a ROCO ROC–COR construct dimerises in a GDP-bound state and that GTP-binding results in monomerization and GTP hydrolysis [34]; however, it is unclear to date if a similar GDP/GTP cycle would apply to the full-length LRRK2 protein. It is tempting to speculate that elaborating on the current structure in a GTP-bound state would provide pivotal clues to further illuminate LRRK2 function and the roles that specific residues might play therein. Notably, the active/inactive conformation of LRRK2 will be of relevance to our understanding of how type I and type II kinase inhibitors interact with and modulate LRRK2 [35]. Elucidating the dynamic interplay between GDP-bound and GTP-bound states, and monomeric and dimeric protein conformations remains a challenge in structural biology that is acutely relevant in the case of LRRK2.

Taken together, these LRRK2 structures present a major step forward for the field, facilitating the generation of testable structure-based hypotheses for LRRK2 biology and pathobiology. At the same time, they act to highlight the limits of our understanding of the molecular function of this protein. The most recent full-length structure has revealed complex LRRK2 inter-domain interactions, further clarified the mechanistic impact of the LRRK2 kinase mutations but stopped short in eluding the underlying mechanism of the LRRK2 ROC–COR domain mutations. Therefore, gaining further insights into the connection between structure and function will be critical to refine and develop ongoing efforts to target LRRK2 in Parkinson's, for example by illuminating the allosteric consequences of kinase inhibition and the distinctions between structurally dissimilar compounds [36]. In addition, testing whether there is a convergent structural and biochemical impact of the different coding mutations and risk variants in LRRK2 linked to Parkinson's disease is still, 17 years after the first description of mutations in LRRK2, a key priority for the field [37]. As new structures become available building on these recent successes, they will provide hope that we are entering a new phase of LRRK2 research where this may, at last, be possible.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

P.A.L. is supported by the Medical Research Council (MR/N026004/1), Parkinson's UK (PRO-20-15), and the Michael J. Fox Foundation (grants 18285 and 18651).

Open Access Statement

Open access for this article was enabled by the participation of University College London in an all-inclusive *Read & Publish* pilot with Portland Press and the Biochemical Society under a transformative agreement with JISC.

Acknowledgements

This research was funded in whole or in part by Aligning Science Across Parkinson's (ASAP0478) through the Michael J. Fox Foundation for Parkinson's Research (MJFF). For the purpose of open access, the author has applied a CC BY public copyright license to all Author Accepted Manuscripts arising from this submission.

Abbreviations

EM, electron microscopy; GAD, G-protein activated by nucleotide-dependent dimerisation; GAPs, GTPase-activating proteins; GEFs, guanine-nucleotide exchange factors; LRRK2, leucine-rich repeat kinase 2; PD, Parkinson's disease.

References

- Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* **44**, 601–607 <https://doi.org/10.1016/j.neuron.2004.11.005>
- Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* **44**, 595–600 <https://doi.org/10.1016/j.neuron.2004.10.023>
- Lewis, P.A. (2019) Leucine rich repeat kinase 2: a paradigm for pleiotropy. *J. Physiol.* **597**, 3511–3521 <https://doi.org/10.1113/JP276163>
- Jabbari, E., Koga, S., Valentino, R.R., Reynolds, R.H., Ferrari, R., Tan, M.M.X. et al. (2021) Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. *Lancet. Neurol.* **20**, 107–116 [https://doi.org/10.1016/S1474-4422\(20\)30394-X](https://doi.org/10.1016/S1474-4422(20)30394-X)
- Blauwendraat, C., Nalls, M.A. and Singleton, A.B. (2020) The genetic architecture of Parkinson's disease. *Lancet. Neurol.* **19**, 170–178 [https://doi.org/10.1016/S1474-4422\(19\)30287-X](https://doi.org/10.1016/S1474-4422(19)30287-X)
- Trabzuni, D., Rytan, M., Emmett, W., Ramasamy, A., Lackner, K.J., Zeller, T. et al. (2013) Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus. *PLoS One* **8**, e70724 <https://doi.org/10.1371/journal.pone.0070724>
- Cogo, S., Greggio, E. and Lewis, P.A. (2017) Leucine rich repeat kinase 2: beyond Parkinson's and beyond kinase inhibitors. *Expert Opin. Ther. Targets* **21**, 751–753 <https://doi.org/10.1080/14728222.2017.1342968>
- Bosgraaf, L. and Van Haastert, P.J. (2003) Roc, a Ras/GTPase domain in complex proteins. *Biochim. Biophys. Acta* **1643**, 5–10 <https://doi.org/10.1016/j.bbamcr.2003.08.008>
- Civiero, L., Dihanich, S., Lewis, P.A. and Greggio, E. (2014) Genetic, structural, and molecular insights into the function of Ras of complex proteins domains. *Chem. Biol.* **21**, 809–818 <https://doi.org/10.1016/j.chembiol.2014.05.010>
- Martens, S., Hofmans, S., Declercq, W., Augustyns, K. and Vandenabeele, P. (2020) Inhibitors targeting RIPK1/RIPK3: old and new drugs. *Trends Pharmacol. Sci.* **41**, 209–224 <https://doi.org/10.1016/j.tips.2020.01.002>
- Skibinski, G., Nakamura, K., Cookson, M.R. and Finkbeiner, S. (2014) Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. *J. Neurosci.* **34**, 418–433 <https://doi.org/10.1523/JNEUROSCI.2712-13.2014>
- Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. *Neurobiol. Dis.* **23**, 329–341 <https://doi.org/10.1016/j.nbd.2006.04.001>
- Deng, J., Lewis, P.A., Greggio, E., Sluch, E., Beilina, A. and Cookson, M.R. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. *Proc. Natl Acad. Sci. U.S.A.* **105**, 1499–1504 <https://doi.org/10.1073/pnas.0709098105>
- Gotthardt, K., Weyand, M., Kortholt, A., Van Haastert, P.J. and Wittinghofer, A. (2008) Structure of the Roc-COR domain tandem of *C. tepidum*, a prokaryotic homologue of the human LRRK2 Parkinson kinase. *EMBO J.* **27**, 2239–2249 <https://doi.org/10.1038/emboj.2008.150>
- Gilsbach, B.K., Ho, F.Y., Vetter, I.R., van Haastert, P.J., Wittinghofer, A. and Kortholt, A. (2012) Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. *Proc. Natl Acad. Sci. U.S.A.* **109**, 10322–10327 <https://doi.org/10.1073/pnas.1203223109>
- Liao, J., Wu, C.X., Burlak, C., Zhang, S., Sahm, H., Wang, M. et al. (2014) Parkinson disease-associated mutation R1441H in LRRK2 prolongs the 'active state' of its GTPase domain. *Proc. Natl Acad. Sci. U.S.A.* **111**, 4055–4060 <https://doi.org/10.1073/pnas.1323285111>
- Guañitoli, G., Raimondi, F., Gilsbach, B.K., Gomez-Llorente, Y., Deyaert, E., Renzi, F. et al. (2016) Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts. *Proc. Natl Acad. Sci. U.S.A.* **113**, E4357–E4366 <https://doi.org/10.1073/pnas.1523708113>
- Sejwal, K., Chami, M., Remigy, H., Vancraenenbroeck, R., Sibrán, W., Sutterlin, R. et al. (2017) Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes. *Sci. Rep.* **7**, 8667 <https://doi.org/10.1038/s41598-017-09126-z>
- Zhang, P., Fan, Y., Ru, H., Wang, L., Magupalli, V.G., Taylor, S.S. et al. (2019) Crystal structure of the WD40 domain dimer of LRRK2. *Proc. Natl Acad. Sci. U.S.A.* **116**, 1579–1584 <https://doi.org/10.1073/pnas.1817889116>
- Deyaert, E., Leemans, M., Singh, R.K., Gallardo, R., Steyaert, J., Kortholt, A. et al. (2019) Structure and nucleotide-induced conformational dynamics of the *Chlorobium tepidum* Roco protein. *Biochem. J.* **476**, 51–66 <https://doi.org/10.1042/BCJ20180803>
- Zhen, Y. and Stenmark, H. (2015) Cellular functions of Rab GTPases at a glance. *J. Cell Sci.* **128**, 3171–3176 <https://doi.org/10.1242/jcs.166074>
- Stafa, K., Trancikova, A., Webber, P.J., Glauser, L., West, A.B. and Moore, D.J. (2012) GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. *PLoS Genet.* **8**, e1002526 <https://doi.org/10.1371/journal.pgen.1002526>
- Biosa, A., Trancikova, A., Civiero, L., Glauser, L., Bubacco, L., Greggio, E. et al. (2012) GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. *Hum. Mol. Genet.* **22**, 1140–1156 <https://doi.org/10.1093/hmg/dd522>
- Gaspar, R., Meyer, S., Gotthardt, K., Sirajuddin, M. and Wittinghofer, A. (2009) It takes two to tango: regulation of G proteins by dimerization. *Nat. Rev. Mol. Cell Biol.* **10**, 423–429 <https://doi.org/10.1038/nrm2689>
- Berwick, D.C., Heaton, G.R., Azeggagh, S. and Harvey, K. (2019) LRRK2 biology from structure to dysfunction: research progresses, but the themes remain the same. *Mol. Neurodegener.* **14**, 49 <https://doi.org/10.1186/s13024-019-0344-2>
- Fung, H.C., Chen, C.M., Hardy, J., Singleton, A.B. and Wu, Y.R. (2006) A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. *BMC Neurol.* **6**, 47 <https://doi.org/10.1186/1471-2377-6-47>
- Rudenko, I.N., Kaganovich, A., Hauser, D.N., Beylina, A., Chia, R., Ding, J. et al. (2012) The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. *Biochem. J.* **446**, 99–111 <https://doi.org/10.1042/BJ20120637>
- Boecker, C.A., Goldsmith, J., Dou, D., Cajka, G.G. and Holzbaur, E.L.F. (2021) Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes. *Curr. Biol.* **31**, 2140–2154.e6 <https://doi.org/10.1016/j.cub.2021.02.061>

- 29 Bonet-Ponce, L., Beilina, A., Williamson, C.D., Lindberg, E., Kluss, J.H., Saez-Atienzar, S. et al. (2020) LRRK2 mediates tubulation and vesicle sorting from lysosomes. *Sci. Adv.* **6**, eabb2454 <https://doi.org/10.1126/sciadv.abb2454>
- 30 Herbst, S., Campbell, P., Harvey, J., Bernard, E.M., Papayannopoulos, V., Wood, N.W. et al. (2020) LRRK2 activation controls the repair of damaged endomembranes in macrophages. *EMBO J.* **39**, e104494 <https://doi.org/10.15252/embj.2020104494>
- 31 Berger, Z., Smith, K.A. and Lavoie, M.J. (2010) Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. *Biochemistry* **49**, 5511–5523 <https://doi.org/10.1021/bi100157u>
- 32 Schapansky, J., Nardozi, J.D., Felizia, F. and LaVoie, M.J. (2014) Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. *Hum. Mol. Genet.* **23**, 4201–4214 <https://doi.org/10.1093/hmg/ddu138>
- 33 Gomez, R.C., Wawro, P., Lis, P., Alessi, D.R. and Pfeffer, S.R. (2019) Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases. *J. Cell Biol.* **218**, 4157–4170 <https://doi.org/10.1083/jcb.201902184>
- 34 Deyaert, E., Wauters, L., Guaitoli, G., Konijnenberg, A., Leemans, M., Terheyden, S. et al. (2017) A homologue of the Parkinson's disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover. *Nat. Commun.* **8**, 1008 <https://doi.org/10.1038/s41467-017-01103-4>
- 35 Roskoski, Jr, R. (2016) Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. *Pharmacol. Res.* **103**, 26–48 <https://doi.org/10.1016/j.phrs.2015.10.021>
- 36 Ding, X. and Ren, F. (2020) Leucine-rich repeat kinase 2 inhibitors: a patent review (2014–present). *Expert Opin. Ther. Pat.* **30**, 275–286 <https://doi.org/10.1080/13543776.2020.1729354>
- 37 Price, A., Manzoni, C., Cookson, M.R. and Lewis, P.A. (2018) The LRRK2 signalling system. *Cell Tissue Res.* **373**, 39–50 <https://doi.org/10.1007/s00441-017-2759-9>
- 38 Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C. et al. (2004) UCSF chimera—a visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–1612 <https://doi.org/10.1002/jcc.20084>
- 39 Deniston, C.K., Salogiannis, J., Mathea, S., Snead, D.M., Lahiri, I., Matyszewski, M. et al. (2020) Structure of LRRK2 in Parkinson's disease and model for microtubule interaction. *Nature* **588**, 344–349 <https://doi.org/10.1038/s41586-020-2673-2>
- 40 Watanabe, R., Buschauer, R., Bohning, J., Audagnotto, M., Lasker, K., Lu, T.W. et al. (2020) The In situ structure of Parkinson's disease-linked LRRK2. *Cell* **182**, 1508–1518.e1516 <https://doi.org/10.1016/j.cell.2020.08.004>
- 41 Myasnikov, A., Zhu, H., Hixson, P., Xie, B., Yu, K., Pitre, A. et al. (2021) Structural analysis of the full-length human LRRK2. *Cell* **184**, 3519–3527.e3510 <https://doi.org/10.1016/j.cell.2021.05.004>